Teva Pharmaceutical Industries (TEVA) Current Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Current Assets for 18 consecutive years, with $13.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 9.03% year-over-year to $13.8 billion; the trailing twelve-month figure through Jun 2026 stood at $13.8 billion (up 9.03% YoY), and the FY2025 full-year result was $13.9 billion, up 11.11% from the prior year.
• Current Assets was little changed at $13.8 billion in Q2 2026 per TEVA's latest filing, from $13.7 billion in the prior quarter.
• Across five years, Current Assets topped out at $13.9 billion in Q4 2025 and bottomed at $11.4 billion in Q3 2023.
• Historically, Current Assets has averaged $12.4 billion across 5 years, with a median of $12.3 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Current Assets dropped 7.63% in 2023, then rose 18.93% in 2026.
• Over 5 years, Current Assets stood at $12.1 billion in 2022, then advanced by 3.6% to $12.5 billion in 2023, then climbed by 0.54% to $12.6 billion in 2024, then advanced by 11.11% to $13.9 billion in 2025, then fell by 1.33% to $13.8 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $13.8 billion, $13.7 billion, and $13.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.